당뇨병성 신경병증 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of diabetic neuropathy Market

The global diabetic neuropathy market size was valued at USD 5.15 billion in 2025 and is projected to reach USD 5.60 billion in 2026 and USD 11.06 billion by 2034. The market is being driven by the increasing prevalence of diabetes, growing awareness of diabetic nerve complications, rising healthcare expenditure, and the introduction of advanced treatment and drug-delivery technologies. North America dominated the market with a 60.66% share in 2025, supported by a high diabetes burden, advanced healthcare infrastructure, and early adoption of innovative therapies.

Market Definition and Scope

Diabetic neuropathy is a diabetes-related nerve disorder caused primarily by prolonged elevated blood glucose levels. It can affect peripheral nerves in the legs and feet as well as nerves associated with digestion, urinary function, cardiovascular activity, and other bodily systems. The market includes therapeutic products and treatment approaches targeting peripheral, autonomic, proximal, and focal neuropathy. Growing diabetes prevalence, an aging population, and increasing demand for effective pain-management therapies are expanding the market outlook.

Market Trends

Technologically Advanced Drug Delivery Systems

The development of technologically advanced drug-delivery systems is an important trend shaping the diabetic neuropathy market. Manufacturers are increasingly exploring transdermal patches, oral formulations, mouth sprays, powders, and needle-free injection technologies to improve patient convenience and reduce discomfort associated with conventional invasive therapies. The growing focus on patient-friendly administration methods is encouraging pharmaceutical companies to strengthen research and product development activities.

Market Dynamics

Drivers

Rising Prevalence of Diabetes

The increasing global diabetic population is a major factor supporting market growth. Sedentary lifestyles, obesity, unhealthy dietary habits, urbanization, and inadequate glucose control contribute to the rising incidence of diabetes and related nerve complications. Increasing awareness about early diagnosis and treatment is also encouraging patients to seek neuropathy therapies.

Launch of Advanced Products

Pharmaceutical companies are expanding their portfolios through new pain-management drugs and innovative therapies. Continued research and development, increasing healthcare expenditure, and growing demand for effective treatment options are creating opportunities for manufacturers.

Restraints

High Treatment Costs and Alternative Therapies

High costs associated with certain neuropathy medications can restrict adoption, particularly in price-sensitive markets. Alternative approaches such as physiotherapy and other supportive treatments may also reduce dependence on pharmaceutical therapies. In addition, stringent regulatory requirements, product recalls, and delays in approvals can affect product launches.

Segmentation Analysis

By Disease Type

The market is segmented into peripheral, autonomic, proximal, and focal diabetic neuropathy. The peripheral segment dominated the market because it represents a common form of diabetic nerve damage, particularly affecting the legs and feet. Increasing awareness and diagnosis are supporting demand for peripheral neuropathy treatments. The autonomic segment is also expected to demonstrate strong growth due to the increasing diabetic population and demand for safe and effective therapies.

By Drug Class

The market includes non-steroidal anti-inflammatory drugs, opioids, antidepressants, anti-seizure medications, and others. Non-steroidal anti-inflammatory drugs held a leading position due to their widespread use for managing pain and inflammation. The opioid segment is expected to experience notable growth as new pain-management formulations and therapies become available.

By Distribution Channel

The market is divided into hospital pharmacies, retail pharmacies and stores, and online pharmacies. Hospital pharmacies accounted for 46.2% in 2025, supported by the increasing number of diabetic patients receiving routine monitoring and treatment in hospitals. Online pharmacies are also gaining importance because they provide convenient access to medications.

Regional Insights

North America

North America remained the leading regional market, supported by high diabetes prevalence, advanced healthcare infrastructure, early adoption of innovative therapies, and strong pharmaceutical development. The U.S. accounted for a substantial portion of regional demand, supported by a large diagnosed diabetic population.

Europe

Europe represented the second-largest regional contributor. Rising healthcare expenditure, an aging population, increasing diabetes prevalence, and pharmaceutical research activities are supporting market development. The region is expected to maintain steady growth as awareness of diabetic complications increases.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region due to the increasing prevalence of diabetes, obesity-related complications, improving healthcare infrastructure, government awareness initiatives, and growing adoption of advanced medicines. China is expected to record strong market expansion.

Japan

Japan represents an important market because of its aging population and increasing incidence of diabetes. The diabetic neuropathy market in Japan is expected to reach USD 218.3 million by 2025, supported by growing demand for effective neuropathic pain treatments.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are expected to experience gradual development. Healthcare infrastructure limitations, lower awareness, and restricted funding remain challenges, although improving healthcare access and diabetes-management initiatives could create future opportunities.

Competitive Landscape

Leading companies operating in the diabetic neuropathy market include Eli Lilly and Company, Pfizer Inc., Abbott, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., and Astellas Pharma US, Inc. Eli Lilly and Company and Pfizer Inc. maintain strong positions through established therapeutic portfolios and continued product development.

Key Industry Developments

In April 2019, Daiichi Sankyo launched Tarlige tablets, containing mirogabalin besilate, for peripheral neuropathic pain treatment in Japan. In October 2018, Ionis Pharmaceuticals and Akcea Therapeutics initiated a Phase III clinical trial of AKCEA-TTR-L for polyneuropathy associated with hereditary TTR amyloidosis.

Report Coverage

The diabetic neuropathy market report covers market segmentation by disease type, drug class, and distribution channel, along with regional analysis and competitive assessment. It evaluates major growth drivers, restraints, emerging treatment technologies, product launches, research and development activities, and changing treatment preferences. The report also highlights major companies and important industry developments influencing the market through 2034.

Conclusion

The diabetic neuropathy market size is expected to expand from USD 5.15 billion in 2025 to USD 5.60 billion in 2026 and USD 11.06 billion by 2034. Rising diabetes prevalence, increasing awareness of nerve-related complications, advanced drug-delivery technologies, and expanding pharmaceutical research are expected to remain central to market development. North America currently leads the market, while Asia Pacific offers significant growth opportunities due to its expanding diabetic population and improving healthcare awareness.

Unit Value (USD billion)

Segmentation By Disease Type

• Peripheral
• Autonomic
• Proximal
• Focal

By Drug Class

• Non-Steroidal Anti-Inflammatory Drugs
• Opioid
• Anti-Depressants
• Anti-Seizure
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
• 4.2. New Product Launches
• 4.3. Prevalence of Diabetic Neuropathy
• 4.4. Pipeline Analysis

5. Global Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Disease Type
  • 5.2.1. Peripheral
  • 5.2.2. Autonomic
  • 5.2.3. Proximal
  • 5.2.4. Focal
• 5.3. Market Analysis, Insights and Forecast - By Drug Class
  • 5.3.1. Non-Steroidal Anti-Inflammatory Drugs
  • 5.3.2. Opioid
  • 5.3.3. Anti-Depressants
  • 5.3.4. Anti-Seizure
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospitals Pharmacies
  • 5.4.2. Retail Pharmacies & Stores
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Country
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Disease Type
  • 6.2.1. Peripheral
  • 6.2.2. Autonomic
  • 6.2.3. Proximal
  • 6.2.4. Focal
• 6.3. Market Analysis - By Drug Class
  • 6.3.1. Non-Steroidal Anti-Inflammatory Drugs
  • 6.3.2. Opioid
  • 6.3.3. Anti-Depressants
  • 6.3.4. Anti-Seizure
  • 6.3.5. Others
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospitals Pharmacies
  • 6.4.2. Retail Pharmacies & Stores
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Disease Type
  • 7.2.1. Peripheral
  • 7.2.2. Autonomic
  • 7.2.3. Proximal
  • 7.2.4. Focal
• 7.3. Market Analysis - By Drug Class
  • 7.3.1. Non-Steroidal Anti-Inflammatory Drugs
  • 7.3.2. Opioid
  • 7.3.3. Anti-Depressants
  • 7.3.4. Anti-Seizure
  • 7.3.5. Others
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospitals Pharmacies
  • 7.4.2. Retail Pharmacies & Stores
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis - By Country/ sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Disease Type
  • 8.2.1. Peripheral
  • 8.2.2. Autonomic
  • 8.2.3. Proximal
  • 8.2.4. Focal
• 8.3. Market Analysis - By Drug Class
  • 8.3.1. Non-Steroidal Anti-Inflammatory Drugs
  • 8.3.2. Opioid
  • 8.3.3. Anti-Depressants
  • 8.3.4. Anti-Seizure
  • 8.3.5. Others
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospitals Pharmacies
  • 8.4.2. Retail Pharmacies & Stores
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis - By Country/ sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Disease Type
  • 9.2.1. Peripheral
  • 9.2.2. Autonomic
  • 9.2.3. Proximal
  • 9.2.4. Focal
• 9.3. Market Analysis - By Drug Class
  • 9.3.1. Non-Steroidal Anti-Inflammatory Drugs
  • 9.3.2. Opioid
  • 9.3.3. Anti-Depressants
  • 9.3.4. Anti-Seizure
  • 9.3.5. Others
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospitals Pharmacies
  • 9.4.2. Retail Pharmacies & Stores
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis - By Country/ sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Diabetic Neuropathy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Disease Type
  • 10.2.1. Peripheral
  • 10.2.2. Autonomic
  • 10.2.3. Proximal
  • 10.2.4. Focal
• 10.3. Market Analysis - By Drug Class
  • 10.3.1. Non-Steroidal Anti-Inflammatory Drugs
  • 10.3.2. Opioid
  • 10.3.3. Anti-Depressants
  • 10.3.4. Anti-Seizure
  • 10.3.5. Others
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospitals Pharmacies
  • 10.4.2. Retail Pharmacies & Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis - By Country/ sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Abbott
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Eli Lilly and Company
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Pfizer.Inc
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. F. Hoffmann-La Roche Ltd
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. GlaxoSmithKline plc.
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Janssen Pharmaceuticals, Inc.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Lupin Pharmaceuticals, Inc.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Astellas Pharma US, Inc.
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Other Prominent Players
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)

12. Strategic Recommendations